Turn Therapeutics Inc.
Turn Therapeutics Inc. is a U.S.-based pharmaceutical and medical device development company built around a proprietary platform for formulating active ingredients in stable oil-based carriers. Its pipeline includes FDA-cleared medical devices, a device under De Novo review, and drug candidates in clinical and pre-clinical development for dermatology and other therapeutic areas.
Fiscal year 2025 · change from previous year
Development 2024–2025
Business
Share of revenueFDA-cleared and in-development devices used for dermatology and related applications.
Pharmaceutical programs in clinical and pre-clinical development, including dermatology and intranasal assets.
PermaFusion formulation technology used to stabilize polar APIs in oil-based carriers.
Out-licensing, development partnerships, and strategic arrangements for product commercialization.
Customers
Turn Therapeutics primarily serves pharmaceutical and medical device partners, regulators, and ultimately patients and clinicians in dermatology and related therapeutic areas. Its commercial model depends on licensing, manufacturing, and distribution partners that can take approved products to market in the U.S. and internationally. The end users for its products include patients with eczema, onychomycosis, and other conditions addressed by its device and drug candidates.
Companies that license Turn's products or platform and handle manufacturing, sales, and distribution.
Dermatology and other clinicians who prescribe or use the company's cleared or approved products.
Individuals with eczema, onychomycosis, and other conditions targeted by the pipeline.
Third parties that may produce or distribute licensed device products.
Strategy
The company is focused on advancing its device and drug pipeline through clinical testing, regulatory submissions, and product validation. A central strategic priority is to secure manufacturing, distribution, and licensing partners that can commercialize approved products without Turn building a large direct sales infrastructure.
Approval is the key gate to product sales and broader commercialization.
Clinical data supports approval, labeling, and partner interest.
Third-party manufacturing and distribution can scale products faster than an internal buildout.
A reusable formulation platform can support multiple products and indications.
Geography
Turn Therapeutics is headquartered in the United States and develops products intended for U.S. and international markets. Its disclosures emphasize commercialization through third-party partners in the U.S. and abroad, so geography matters mainly through regulatory approvals, partner execution, and market access rather than owned manufacturing footprints.
Risks
Turn Therapeutics faces high regulatory and clinical development risk because its business depends on FDA clearances, IND acceptance, and successful trial outcomes. It also depends on external financing and partner execution, which can dilute shareholders or delay commercialization if capital or collaboration terms are unfavorable.
- Regulatory approval riskImpact: CriticalLikelihood: Medium
Products cannot be commercialized until FDA pathways are successfully completed.
Exposure - Financing and dilution riskImpact: HighLikelihood: High
The company expects to fund operations through equity, debt, and other capital sources.
Exposure: Common stock issuances and financing agreements
- Clinical development failure or delayImpact: HighLikelihood: Medium
Trial outcomes determine whether the company can advance to later-stage development and approval.
Exposure: Human eczema trial and planned Phase 3 programs
- Partner execution riskImpact: MediumLikelihood: Medium
Commercial success depends on third parties handling manufacturing, distribution, and sales.
Exposure: Licensing and commercialization arrangements
- Competition and class-wide product riskImpact: MediumLikelihood: Low
Competing therapies or device issues can affect adoption and regulatory expectations.
Exposure: Dermatology and drug-delivery markets
Accounting
Judgemental itemsRecognition is deferred until FDA approval or a reliable estimate of outcomes is possible.
Impact: Can shift revenue recognition across periods
License and service arrangements require judgment on performance obligations and variable consideration.
Impact: Affects timing and amount of reported revenue
Legal and registration costs are recorded as intangible assets and amortized over time.
Impact: Influences asset base and amortization expense
Equity awards and stock-settled advisory services create non-cash expense.
Impact: Affects operating loss and equity dilution
Cash runway and future funding needs are central to financial statement presentation and disclosure.
Impact: Signals financing dependence and survival risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Inhibitor Therapeutics, Inc.
INTI · Pharmaceutical Preparations
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Dermata Therapeutics, Inc.
DRMA · Pharmaceutical Preparations
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026